Showing results (221-230 of 458) with videos related to
Sort By:
Pageof 46
Pediatric Blood & Cancer|June 27, 2013
Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing programAndrew C Wood, John M Maris, Richard Gorlick, et al.Pediatric Blood & Cancer|December 18, 2009
Initial testing of topotecan by the pediatric preclinical testing programHernan Carol, Peter J Houghton, Christopher L Morton, et al.Pediatric Blood & Cancer|March 2, 2011
Initial testing of lenalidomide by the pediatric preclinical testing programC Patrick Reynolds, Min H Kang, Stephen T Keir, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2008
A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumorsElizabeth Fox, John M Maris, Brigitte C Widemann, et al.Pediatric Blood & Cancer|September 25, 2012
Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing programC Patrick Reynolds, Min H Kang, Hernan Carol, et al.Biorxiv : the Preprint Server for Biology|February 13, 2023
<i>BARD1</i> germline variants induce haploinsufficiency and DNA repair defects in neuroblastomaMichael P Randall, Laura E Egolf, Zalman Vaksman, et al.Journal of the National Cancer Institute|September 9, 2023
BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastomaMichael P Randall, Laura E Egolf, Zalman Vaksman, et al.Pediatric Blood & Cancer|November 22, 2011
Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing ProgramRichard Gorlick, John M Maris, Peter J Houghton, et al.Pediatric Blood & Cancer|October 27, 2009
Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing programMalcolm A Smith, Christopher L Morton, E Anders Kolb, et al.Pediatric Blood & Cancer|October 22, 2008
Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology GroupJulie R Park, Judith G Villablanca, Wendy B London, et al.Pageof 46